Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

KYTH 50.15 +1.37 (2.81%)
price chart
Why Kythera Biopharmaceuticals, Inc Rocketed Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
FDA staff backs injection to reduce double chin  Fox News
KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common ...
WESTLAKE VILLAGE, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the pricing of its underwritten public offering of 2,604,168 shares of its common stock at a price to the public of $48.00 ...
KYTHERA Biopharmaceuticals Announces FDA Advisory Committee ...  CNNMoney
FDA Panel Backs Kythera Double-Chin Treatment  Wall Street Journal
Commit To Buy Kythera Biopharmaceuticals At $30, Earn 11.9% Annualized ...
Investors eyeing a purchase of Kythera Biopharmaceuticals, Inc. (Symbol: KYTH) stock, but cautious about paying the going market price of $49.86/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Kythera Biopharmaceuticals Inc. (KYTH) is Trading Higher on Unusual Volume ...
Kythera Biopharmaceuticals (KYTH) Enters Overbought Territory
Kythera Biopharmaceuticals, Inc. Short Interest Disclosure
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH), In a major negative the short interest in Kythera Biopharmaceuticals, Inc. shot up by 2.1% or 105,990 shares. The final shorts are 32.7% of the total floated shares. The positions increased from 5,086,896 ...
Climbing Stocks Investor's Alert - Kythera Biopharmaceuticals, (NASDAQ ...  wsnewspublishers
Kythera Biopharmaceuticals Director Sells $340175.00 in Stock (KYTH)  sleekmoney
KYTHERA Biopharmaceuticals Announces 2015 Outlook Call
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
Kythera Biopharmaceuticals Inc. (KYTH) Hits New 52-week High During March ...
Kythera Biopharmaceuticals Inc. (KYTH) hit a new 52-week high yesterday, reaching a peak of $53.68 after opening at $49.90 and closing at $53.14 for a move of $6.28%.
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
WESTLAKE VILLAGE, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
Related articles »  
Short Interest of Kythera Biopharmaceuticals Inc Drops by 0.2%
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) reported a drop of 0.2% or 9,314 shares in its short interest. The short figure came in at 28.7% of the total floats.
Bullish and Outperform S&P 500: Kythera Biopharmaceuticals Inc , Town ...  Ashburn Daily
Kythera Biopharmaceuticals, Inc. Price Target Update
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH): The mean estimate for the short term price target for Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) stands at $56.25 according to 4 Analysts. But, the investors should remain cautious as the stock may ...
KYTHERA Biopharmaceuticals Announces 2014 Operating Results  GlobeNewswire (press release)
KYTHERA Biopharmaceuticals to Present at the 2015 Leerink Global Healthcare ...
WESTLAKE VILLAGE, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference.
KYTHERA Biopharmaceuticals Submits Drug Application in Australia for Novel ...  Nasdaq